Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases (2006)

Peer-Reviewed Study · Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. · May 1, 2006

Vauthey JN et al., 2006-05-01: Pathologic study of 406 livers resected for colorectal metastases. Irinotecan was associated with steatohepatitis (20.2% vs 4.4% without chemotherapy) and oxaliplatin with sinusoidal dilation; steatohepatitis carried a 14.7% vs 1.6% 90-day mortality.

irinotecan was associated with steatohepatitis compared with no chemotherapy (20.2% v 4.4%, respectively; P < .001; OR = 5.4; 95% CI, 2.2 to 13.5)

Abstract (Results)

Vauthey JN et al., 2006-05-01: Pathologic study of 406 livers resected for colorectal metastases. Irinotecan was associated with steatohepatitis (20.2% vs 4.4% without chemotherapy) and oxaliplatin with sinusoidal dilation; steatohepatitis carried a 14.7% vs 1.6% 90-day mortality. Comparator: no preoperative chemotherapy (158 patients). Funder/COI not in the abstract. This is the primary evidence behind 'chemo-associated steatohepatitis' and it is the reason the 70% figure cannot stand: the measured injury rates are 8.4% steatohepatitis overall, 20.2% in the irinotecan subgroup, and 5.4% sinusoidal dilation – nowhere near 70%. Study type: controlled study.